PTCT Form 4: Director exercises options, now holds 6,666 shares

Rhea-AI Filing Summary

PTC Therapeutics director reports stock option exercise and sale. A board member of PTC Therapeutics, Inc. (PTCT) exercised stock options for 10,000 shares of common stock at an exercise price of $51.16 per share on 11/21/2025. On the same day, the director sold 10,000 shares of common stock at a price of $79.50 per share. After these transactions, the director beneficially owned 6,666 shares of PTCT common stock directly. The option exercise was reported as a stock option (right to buy) that was already exercisable and carries an expiration date of 01/28/2030. The filing notes that the transactions were carried out under a pre‑established Rule 10b5‑1 trading plan adopted on March 4, 2025, which is designed to allow trading under predetermined conditions.

Insider Trade Summary

Net Seller: 10,000 shares ($795,000)

Net Sell 3 txns

Insider Reeve Emma

Role Director

Sold 10,000 shs ($795K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	10,000	$0.00	--
Exercise	Common Stock	10,000	$51.16	$512K
Sale	Common Stock	10,000	$79.50	$795K

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 16,666 shares (Direct)

Footnotes (1)

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025 Currently exercisable.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reeve Emma

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/21/2025		M(1)		10,000	A	$51.16	16,666	D
Common Stock	11/21/2025		S(1)		10,000	D	$79.5	6,666	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$51.16	11/21/2025		M(1)			10,000	(2)	01/28/2030	Common Stock	10,000	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025

2. Currently exercisable.

	/s/ Avraham S. Adler, Attorney-in-Fact	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PTC Therapeutics (PTCT) report in this Form 4?

The filing shows a director of PTC Therapeutics (PTCT) exercised stock options for 10,000 shares at $51.16 per share and sold 10,000 shares at $79.50 per share on 11/21/2025.

How many PTC Therapeutics (PTCT) shares does the director own after the transactions?

After the reported transactions, the director beneficially owned 6,666 shares of PTC Therapeutics common stock in direct ownership.

What type of derivative security was involved in the PTC Therapeutics (PTCT) Form 4?

The derivative security was a stock option (right to buy) for 10,000 shares of PTCT common stock with an exercise price of $51.16 per share and an expiration date of 01/28/2030.

Were the PTC Therapeutics (PTCT) insider trades under a Rule 10b5-1 plan?

Yes. The filing states that the transactions were effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2025.

What is the relationship of the reporting person to PTC Therapeutics (PTCT)?

The reporting person is identified as a director of PTC Therapeutics, Inc. and filed the Form 4 as a single reporting person.

On what date did the earliest reported PTC Therapeutics (PTCT) transaction occur?

The earliest transaction date reported in this Form 4 is 11/21/2025.